[Quality of life of patients suffering from osteoporosis treated with alendronate and salmon calcitonin].
Osteoporosis is a disease of skeletal system characterized by low bone mass, disturbed bone tissue microarchitecture which lead to high risk fractures. Pharmacological treatment of patients suffering from osteoporosis is long-term. Anti reabsorption drugs as alendronate and nasal salmon calcitonin have antifracture effect confirmed in accordance with Evidence Based Medicine but they differ in administration, tolerance, side effects which result in patients' quality of life. The study comparing influence of treatment on quality of life was carried out on the group of 78 women who were patients of Medical Rehabilitation Ward and outpatient clinic of John Paul II Hospital in Zamość. All patients underwent densitometry (DEXA) which confirmed osteoporosis (BMD: T-score < -2.5 SD). Patients' age ranged from 52 to 73. 46 women were treated with nasal calcitonin and 32 with alendronate. The observation lasted 6 months. Questionnaire was used in the study. Comfort and quality of life were evaluated in the study (comfort of administration, painkilling effect, necessity of additional painkillers and drug tolerance. We also studied which of the drugs better improved patients' life activity. Apart from pharmacotherapy patients were also treated with kinesitherapy, physical activity and with 1000 mg Calcium and 400 u. Vit. D. We used test chi 2 in the study. We stated (p < 0.001) better quality of life in those patients who used nasal salmon calcitonin. It is very important when we take into consideration that patients suffering from osteoporosis should be treated till the end of life. Osteoporosis treatment should be joint therapy including prevention, rehabilitation and pharmacology.
Zakładu Zarzadzania i Ekonomiki Ochrony Zdrowia Akademii Medycznej w Lublinie.
Rafał A
RA
Sapuła
Tomasz
T
Ostrowski
Iwona
I
Bojar
D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D011044:Poland; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome; D016387:Women's Health
D002136:Calcium, Dietary; D002116:Calcitonin; D019386:Alendronate